fashion -WSS

fashion

author：explore 2025-08-26 02:43:29 - browse：81

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Air quality improving but still lags in Black, Hispanic communities

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

What it’s like to watch children die of measles

UnitedHealth quietly bought dozens of outpatient centers

Cheap, fast test for Zika and dengue could cost just $1

Cheap, fast test for Zika and dengue could cost just $1

Deposition: Sackler embraced plan to conceal OxyContin’s strength

hotspot

fashion

focus

Medical leaders decry Supreme Court decision on affirmative action

Coercive sterilizations revealed by STAT prompt outrage

Cancer drug shortages should be causing more outrage

IVF, abortion rights issues kick off Biden’s State of the Union

Guidelines to prevent youth baseball injuries need more muscle

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

State Dept. review finds Biden bears some blame for Afghanistan failures

California wildfire smoke linked to 52,000 early deaths, study says

Guidelines to prevent youth baseball injuries need more muscle

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

focus

The problem with charging patients to message their doctors

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

IVF, abortion rights issues kick off Biden’s State of the Union

Study: Why relieving medical debt did not improve financial outcomes

Curing rare childhood diseases will falter unless Congress steps up

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

focus

focus

leisure time

explore